Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis

Show other versions (1)

<strong>Objective</strong> To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis...

Full description

Bibliographic Details
Main Authors:	Taylor, P, Weinblatt, M, Burmester, G, Rooney, T, Witt, S, Walls, C, Issa, M, Salinas, C, Saifan, C, Zhang, X, Cardoso, A, Gonzalez-Gay, M, Takeuchi, T
Format:	Journal article
Published:	Wiley 2019

Similar Items

Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis
by: Weinblatt, M, et al.
Published: (2017)

Cardiovascular safety - Update from up to 6 years of treatment with baricitinib in rheumatoid arthritis clinical trials
by: Weinblatt, M, et al.
Published: (2018)

Baricitinib versus placebo or adalimumab in rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
by: Taylor, P, et al.
Published: (2016)

Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis
by: Taylor, P, et al.
Published: (2017)

Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 9.3 years: an updated integrated safety analysis
by: Taylor, P, et al.
Published: (2022)

Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis
by: Weinblatt, M, et al.
Published: (2018)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: Results from a long-term study
by: Smolen, JS, et al.
Published: (2020)

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study
by: Smolen, JS, et al.
Published: (2020)

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
by: Taylor, P, et al.
Published: (2019)

Baricitinib for the treatment of rheumatoid arthritis
by: Ivan Urits, et al.
Published: (2020-12-01)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
by: Keystone, E, et al.
Published: (2015)

Baricitinib: Early vs. delayed start in patients with rheumatoid arthritis
by: Taylor, P, et al.
Published: (2018)

Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis
by: Tanaka, Y, et al.
Published: (2018)

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
by: Taylor, P, et al.
Published: (2021)

Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis
by: Keystone, EC, et al.
Published: (2017)

Rapid and sustained pain improvement in rheumatoid arthritis patients treated with baricitinib compared to adalimumab or placebo
by: Taylor, P, et al.
Published: (2017)

Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study
by: Emery, P, et al.
Published: (2017)

A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience
by: Taylor, PC, et al.
Published: (2023)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
by: Peter C. Taylor, et al.
Published: (2023-07-01)

Baricitinib exposure during pregnancy in rheumatoid arthritis
by: Giulia Costanzo, et al.
Published: (2020-01-01)

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis
by: Naoki Iwamoto, et al.
Published: (2021-07-01)

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
by: Taylor, P, et al.
Published: (2022)

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
by: Keystone, E, et al.
Published: (2017)

Patient disease trajectories in rheumatoid arthritis patients treated with baricitinib 4-mg in 4 phase 3 clinical studies
by: Taylor, PC, et al.
Published: (2023)

New alternative in the treatment of rheumatoid arthritis: clinical utility of baricitinib
by: Kawalec P, et al.
Published: (2019-02-01)

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies
by: Peter C. Taylor, et al.
Published: (2023-01-01)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
by: Paul Emery, et al.
Published: (2020-05-01)

Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib
by: Robert Harrington, et al.
Published: (2023-10-01)

Assessment of pain improvement in rheumatoid arthritis patients treated with baricitinib, who were inadequate responders to methotrexate and tumor necrosis factor inhibitors
by: Taylor, P, et al.
Published: (2019)

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
by: Tanaka, Y, et al.
Published: (2019)

Achieving pain control in rheumatoid arthritis with baricitinib or ddalimumab plus methotrexate: Results from the RA-BEAM Trial
by: Taylor, P, et al.
Published: (2019)

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
by: Paul Emery, et al.
Published: (2020-07-01)

Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis
by: Cristina Martinez-Molina, et al.
Published: (2024-02-01)

Problems of pain and quality of life in rheumatoid arthritis: focus on baricitinib
by: A. E. Karateev
Published: (2020-09-01)

Baricitinib provides greater improvements in patient-reported outcomes across all disease activity levels compared to placebo and adalimumab in rheumatoid arthritis
by: Taylor, P, et al.
Published: (2021)

Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis
by: Emery, P, et al.
Published: (2019)

Lack of clinical disease activity response at 4 weeks of baricitinib treatment as a negative predictor of remission at weeks 12 and 24 in patients with rheumatoid arthritis: results from two phase 3 studies (RA-BEAM and RA-BEGIN)
by: Tanaka, Y, et al.
Published: (2021)

Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis
by: Dimitra Koumaki, et al.
Published: (2019-12-01)

Rapid and concurrent improvements in patient-reported outcomes of rheumatoid arthritis with baricitinib in RA-BEAM
by: Strand, V, et al.
Published: (2021)